The purpose of the agreement is to avoid misunderstandings concerning the medications that you will be utilizing to manage anxiety and related conditions. The agreement aims at helping you as well as your provider to follow the legal process concerning controlled pharmaceuticals. You should note that using the Benzodiazepines medications might result in addiction and other health complications while they should only be used on pain management.
The purpose of the medicines include
To improve your ability to operate efficiently in the workplace and capacity for functioning well at tome
Delegate your assignment to our experts and they will do the rest.
To improve my physical wellbeing as much as possible without leading to devastating side effects
I agree to the following
I will take the medications according to the prescriptions by the physician
I will refrain from sharing the medication with other people claiming to have similar or related conditions
I agree to ensure that I inform my provider regarding the following
Of the different controlled substances that I have used previously whether prescribed or otherwise
Whether I take alcohol or other kinds of drugs while utilizing the controlled substances
Whether I have received treatment for complications or side effects associated with the utilization of the controlled substances, including whether I have encountered any incidences of overdose
Any other region or state that I have resided earlier or a prescription I received for a controlled substance
I agree to monitoring and testing of usage of drug when provider regards the case as necessary
I agree that my provider might count the prescribed pills in my possession randomly to determine whether there have been any incidences of overdose
I understand that my provider might discontinue or change the controlled pain management treatment for the following reasons
In case I am found to have overdosed the medication
I fail to follow the required schedule for taking the medication
If I experience any side effects as a result of using the medication
Other conditions that the provider might deem appropriate for discontinuing or changing the medication
(Name and Signature of Patient) (Name and Signature of Provider)
Reflection
When drafting the controlled substance contract, I thought of the serious implications that Benzodiazepines medications might bring to patients in the event of misuse or incorrect dosage. As such, it became essential to ensure that the patient and the prescribing provider signed the agreement while outlining the responsibilities and guidelines between the two parties. These targeted the expectations and behaviors surrounding the prescription of Benzodiazepines. The agreement ensured to lay major emphasis on regulatory oversight while at the same time allowing the physician a means of communicating with the patients regarding what to anticipate when experiencing anxiety (Tobin, Keough Forte, & Johnson McGee, 2016) . In this manner, the provider and the patient would comply around the laws and regulations surrounding the controlled substance.
The policy/contract is supported by evidence/research. Here, studies reveal that anxiety serves as among the major reasons as to why individuals result to Benzodiazepines prescription. Within the U.S., for instance, a considerable number of adults experience anxiety on a daily basis while undertaking their duties, including work, social situations, or even in their households (Philpot, et al., 2017) . In addition, a number of patients usually seek primary care face intense anxiety, which lead them to seek medication related to allow them to cope with the condition. Medications for treating anxiety and associated conditions are among the most utilized in allowing patients to deal with the condition, although their efficiency during the long-term is unproven. In this sense, the development anxiety controlled substance contracts is a mitigation approach to clinical risk with clinical guidelines recommending them. These are crucial agreements that offer education while requiring mutual consent between providers and patients informing patients regarding their responsibilities when utilizing prescribed Benzodiazepines medications (Khalid, et al., 2015) . These have been attributed to modest reductions in the event that patients misuse them.
The policy/contract will benefit my PMHNP practice is such a manner that it will provide an avenue for collaborating with other care professionals to offer prescription services. This is particularly the case since Benzodiazepines medications have side effects, some of which might affect the mental health of individuals. In this sense, it will be possible to gain advanced knowledge on how prescription medicines work in line with their implications toward patients, particularly their mental states (Khalid, et al., 2015) . This way, it will be possible to direct sufficient attention to the prescription process to ensure that patients receive the appropriate dosage based on their condition.
When implementing the policy/contract to my future PMHNP, a major challenge that I foresee is one related to failure by patients to follow the guidelines, which will affect their health negatively. I also foresee the challenge of patients seeking the medications from other sources, some of which might be dealing with counterfeit products (Paulozzi, Strickler, Kreiner, & Koris, 2015) . However, when questioned by a patient and or the patient’s family regarding my policy/contract, I will ensure to illustrate using examples on the need for following the guidelines and the repercussions that might result due to failure to abide by them, such as legal action or even severe health implications.
References
Khalid, L., Liebschutz, J. M., Xuan, Z., Dossabhoy, S., Kim, Y., Crooks, D., & Lasser, K. E. (2015). Adherence to prescription opioid monitoring guidelines among residents and attending physicians in the primary care setting. Pain Medicine, 16 (3), 480-487.
Paulozzi, L. J., Strickler, G. K., Kreiner, P. W., & Koris, C. M. (2015). Controlled substance prescribing patterns—prescription behavior surveillance system, eight states, 2013. Morbidity and Mortality Weekly Report: Surveillance Summaries, 64 (9), 1-14.
Philpot, L. M., Ramar, P., Elrashidi, M. Y., Mwangi, R., North, F., & Ebbert, J. O. (2017). Controlled substance agreements for opioids in a primary care practice. Journal of Pharmaceutical Policy and Practice, 10 (1), 1-29.
Tobin, D. G., Keough Forte, K., & Johnson McGee, S. (2016). Breaking the pain contract: A better controlled-substance agreement for patients on chronic opioid therapy. Cleve Clin J Med, 83 (11), 827-835.
